Abstract
The use of anti-gene agents to disrupt the expression of disease-related genes could potentially be of utility in the treatment of a large number of illnesses, including most neoplasms. Traditional anti-gene agents include antisense oligonucleotides and ribozymes. Recent observations have provided evidence for another promising anti-gene technology-RNA interference (RNAi), in which the introduced double-stranded RNA (dsRNA), after a complicated series of processing steps, disrupts the expression of the targeted cellular gene. Further studies have indicated that small interfering RNAs (siRNAs) of generally 21 ∼ 23 nucleotides, which resemble the processing products of long dsRNA, can induce RNAi directly in mammalian cells. Because of their high specificity and efficiency, siRNAs might be a new class of anti-gene medicines for gene therapy applications.
Keywords: Gene Therapy, anti-gene medicines, oligonucleotides, ribozymes
Current Gene Therapy
Title: Small Interfering RNA: A New Tool for Gene Therapy
Volume: 3 Issue: 5
Author(s): Feng Bi, Na Liu and Daiming Fan
Affiliation:
Keywords: Gene Therapy, anti-gene medicines, oligonucleotides, ribozymes
Abstract: The use of anti-gene agents to disrupt the expression of disease-related genes could potentially be of utility in the treatment of a large number of illnesses, including most neoplasms. Traditional anti-gene agents include antisense oligonucleotides and ribozymes. Recent observations have provided evidence for another promising anti-gene technology-RNA interference (RNAi), in which the introduced double-stranded RNA (dsRNA), after a complicated series of processing steps, disrupts the expression of the targeted cellular gene. Further studies have indicated that small interfering RNAs (siRNAs) of generally 21 ∼ 23 nucleotides, which resemble the processing products of long dsRNA, can induce RNAi directly in mammalian cells. Because of their high specificity and efficiency, siRNAs might be a new class of anti-gene medicines for gene therapy applications.
Export Options
About this article
Cite this article as:
Bi Feng, Liu Na and Fan Daiming, Small Interfering RNA: A New Tool for Gene Therapy, Current Gene Therapy 2003; 3 (5) . https://dx.doi.org/10.2174/1566523034578203
DOI https://dx.doi.org/10.2174/1566523034578203 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Markers in SIRS, Sepsis and Septic Shock
Current Medicinal Chemistry Neuronal-glial Interactions Define the Role of Nitric Oxide in Neural Functional Processes
Current Neuropharmacology The Role of Glial Cells in Drug Abuse
Current Drug Abuse Reviews Interstitial Cystitis / Painful Bladder Syndrome (IC/PBS) Dilemmas in Diagnosis & Treatment
Current Women`s Health Reviews The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Chediak-Higashi Syndrome: a Clinical and Molecular View of a Rare Lysosomal Storage Disorder
Current Molecular Medicine Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review
Current Pharmaceutical Design An Overview of Valuable Scientific Models for Diabetes Mellitus
Current Diabetes Reviews Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Role of microRNAs in Non-Alcoholic Steatohepatitis
Current Pharmaceutical Design Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review
Current Gene Therapy SDR Structure, Mechanism of Action, and Substrate Recognition
Current Organic Chemistry Biomarkers for Predicting the Immunomodulatory Properties of Probiotics
Recent Patents on Biomarkers Hypercholesterolemia and Endothelium Dysfunction: Role of Dietary Supplementation as Vascular Protective Agents
Current Vascular Pharmacology Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Biphasic Vesicles for Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections
Current Drug Delivery CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry EDITORIAL [Hot topic: Tissue Fibrosis (Guest Editor: Shizuya Saika)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Purine Nucleoside Analogs in the Treatment of Rarer Chronic Lymphoid Leukemias
Current Pharmaceutical Design A Dual Mechanism Linking NGF/proNGF Imbalance and Early Inflammation to Alzheimer's Disease Neurodegeneration in the AD11 Anti-NGF Mouse Model
CNS & Neurological Disorders - Drug Targets